Publications

Peer-Reviewed Journal Papers(“*” stands for corresponding author)
  • Dong H, Hao K, Tian Y, Jin S, Lu H, Zhou SF, & Zhang X. Label-free and ultrasensitive microRNA detection based on novel molecular beacon binding readout and target recycling amplification. Biosensorsand Bioelectronics2014; March 15; 53: 377-383.
  • He JL, Zhou ZW, Yin JJ, He CQ, Yu Y, & Zhou SF*. Schisandra chinensis regulates drug metabolizing enzymes and drug transporters via activation of Nrf2-mediated signaling pathway. Drug Design, Development and Therapy 2014 (accepted in July 2014).
  • He S, Zeng S, Zhou ZW, He ZX, & Zhou SF*. Hsa-microRNA-181a is a regulator of a number of cancer genes and a biomarker for endometrial carcinoma in patients: a bioinformatic and clinical study and the therapeutic implication. Drug Design, Development and Therapy 2014 (accepted in September 25 2014).
  • He ZX, Thach C, & Zhou SF*. Clinical herb-drug interactions as a safety concern in pharmacotherapy. Journal of Pharmacology and Drug Metabolism 2014; 1: e101.
  • He ZX& Zhou SF*. Pharmacogenetics-guided dosing for fluoropyrimidines in cancer chemotherapy. Advances in Pharmacoepidemiology and Drug Safety 2014; 3:e125. doi:10.4172/2167-1052.1000e125.
  • Liang S, Zhou Y, Wang H, Qian Y, Ma D, Tian W, Persaud-Sharma V, Yu C, Ren Y, Zhou SF, & Li X. The effect of multiple single nucleotide polymorphisms in the folic acid pathway genes on homocysteine metabolism. BioMed International Research 2014; Article ID 56018.
  • Li M, Yang Y, He ZX, Zhou ZW, Yang T, Guo P, Zhang X, &SF Zhou*. MicroRNA-561 promotes acetaminophen-induced hepatotoxicity in HepG2 cells and primary human hepatocytes through down-regulation of the nuclear receptor co-repressor dosage-sensitive sex reversal adrenal hypoplasia congenital critical region on X chromosome, gene 1 (DAX-1). Drug Metabolism and Disposition 2014; 42(1): 44-61.
  • Li YC, He SM, He ZX, Li M, Yang Y, Tang JX, Zhang X, Chow K, Zhou Q, Duan W, Zhou ZW, Yang T, Huang GH, Liu A, Qiu JX, Liu JP, & Zhou SF*. Plumbagin induces apoptotic and autophagic cell death through inhibition of the PI3K/Akt/mTOR pathway in human non-small cell lung cancer cells. Cancer Letters2014; 344(2): 239-259.
  • Lin D, La Pena ID, Lin L, Zhou SF*, Borlongan CV, & Cao C. The neuroprotective role of acupuncture and activation of the BDNF signaling pathway. International Journal of Molecular Sciences 2014; 15(2): 3234-3252. doi:10.3390/ijms15023234.
  • Ma K, Jin H, Hu R, Xiong Y, Zhou SF, Pan T, Cheng Y, Yang Y, Yang P, & XT Li. A proteomic analysis of placental trophoblastic cells in preeclampsia–eclampsia. Cell Biochemistry and Biophysics 2014; Jun; 69(2): 247-258. doi: 10.1007/s12013-013-9792-4.
  • Pan SY, Gao SH, Zhou SF, Dong HG, Tang MK, Yu ZL, & Ko KM. New perspectives on dietary-derived treatments and food safety - Antinomy in a new era. Critical Reviews in Food Science and Nutrition 2014; published online. doi:10.1080/10408398.2011.654286.
  • Pan SY, Gao SH, Zhou SF, Litscher G, Chen HQ, Yu ZL, Zhang SF, Tang MK, Sun JN, &Ko KM. Historical perspective of traditional indigenous medical practices: The current renaissance and conservation of herbal resources. Evidence-based Complementary and Alternative Medicine (eCAM) 2014; Volume 2014, Article ID 525340.http://dx.doi.org/10.1155/2014/525340.
  • Qiu JX, Zhou ZW, He ZX, Zhao RJ, Zhang XJ, Yang L, Zhou SF*, & Mao ZF. Plumbagin elicits a proteomic response mainly involving changes in apoptosis, autophagy, and epithelial to mesenchymal transition pathways in human prostate cancer PC-3 and DU145 cells. Drug Design, Development and Therapy 2014 (accepted in August 2014).
  • Shan LX, Sun PH, Guo BQ, Xu XJ, Li ZQ, Sun J, Zhou SF*, & Chen WM. Synthesis and antibacterial activities of acylide derivatives bearing an aryl-tetrazolyl chain. Drug Design, Development and Therapy 2014; Volume 2014 (8): 1515-1525.
  • Shigdar S, Li Y, Bhattacharya S, O'Connor M, Pu C, Lin J, Wang T, Xiang D, Kong L, Wei MQ, Zhu Y, Zhou SF, & Duan W. Inflammation and cancer stem cells. Cancer Letters2014; April 10, 345(2): 271–278.
  • Su J, Chang C, Xiang Q, Zhou ZW, Luo R, Yang L, He ZX, Yang H, Li J, Bei Y, Xu J Zhang M, Zhang Q, Su Z, Huang Y, Pang J, & Zhou SF*. Xyloketal B, a marine compound, acts on a network of molecular proteins and regulates the activity and expression of rat cytochrome P450 3a: A bioinformatic and animal study. Drug Design, Development and Therapy 2014 (accepted in September 24 2014).
  • Sun N, Pan SY, Zhang Y, Wang XY, Zhu PL, Chu ZS, Yu ZJ, Zhou SF, & Ko KM. Dietary pulp from Fructus Schisandra Chinensis supplementation reduces serum/hepatic lipid and hepatic glucose levels in mice fed a normal or high cholesterol/bile salt diet. Lipids in Health and Disease 2014; 13: 46.
  • Wang F, Wang Q, Zhou ZW, Song NY, Pan ST, He ZX, Zhang XJ, Wang D, Yin-Yang YX, Yang T, Sun T, Li M, Qiu JX, & Zhou SF*. Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells. Drug Design, Development and Therapy 2014 (accepted in September 24 2014).
  • Wang F, Lu X, Peng K, Du Y, Zhou SF, Zhang A, & Yang T. Prostaglandin E-prostanoid4 receptor mediates angiotensin II-induced (pro)renin receptor expression in the rat renal medulla. Hypertension 2014; Aug; 64(2): 369-377. doi: 10.1161/HYPERTENSIONAHA.114.03654.
  • Wang F, Lu X, Peng K, Zhou L, Li C, Wang W, Yu X, Kohan D, Zhou SF, & T Yang. COX-2 mediates angiotensin II-induced (pro)renin receptor expression in the rat renal medulla. American Journal of Physiology - Renal Physiology 2014; published online.
  • Wang JY, Li H, Ma CM, Wang JL, Lai XS, & Zhou SF*. MicroRNA profiling response to acupuncture therapy in spontaneously hypertensive rats. Evidence-based Complementary and Alternative Medicine (eCAM) 2014 (accepted in July 2014).
  • Wang JY, Li H, Zhang L, Ma CM, Wang JL, Lai XS, & Zhou SF*. Adenosine as a probing tool for mechanistic study of acupuncture treatment. Clinical and Experimental Pharmacology and Physiology 2014 (accepted in August 2014).
  • Wang XY, Pan SY, Zhang Y, Sun N, Zhu PL, Zhou SF, Yu Z, & Ko KM. Supplementation with the extract of Schisandrae Fructus pulp, seed or their combination influences the metabolism of lipids and glucose in mice fed with normal and hypercholesterolemic diet. Evidence-Based Complementary and Alternative Medicine (eCAM) 2014; volume 2014, Article ID 472638.
  • Wang ZX, Sun J, Howell CE, Zhou QY, He ZX, Yang T, Chew H, Duan W, Zhou ZW, Kanwar JR,& Zhou SF*. Prediction of the likelihood of drug interactions with kinase inhibitors based on in vitro and computational studies. Fundamental & Clinical Pharmacology 2014; 28(5): 551–582.
  • Wang YY, Yang YX, Zhe H, He ZX, & Zhou SF*. Bardoxolone methyl (CDDO-Me) as a therapeutic agent: an update on its pharmacokinetic and pharmacodynamic properties. Drug Design, Development and Therapy 2014 (accepted in July 2014).
  • Wen JB, Zhu FQ, Chen WG, Jiang LP, Chen J, Hu ZP, Jian Huang YJ, Zhou ZW, Wang GL, Lin H, & Zhou SF*. Oxymatrine improves intestinal epithelial barrier function involving NF-κB-mediated signaling pathway in CCl4-induced cirrhotic rats. PLoS One2014 (accepted in August 2014).
  • Xu T, Scafa N, Xu LP, Su L, Li C, Zhou SF, Liu Y, & Zhang X. Electrochemical sensors for nitric oxide detection in biological applications. Electroanalysis 2014; 26(3): 449-468.
  • Zhang LF, Zhou ZW, Wang ZH, Du YH, He ZX, Cao C, & Zhou SF*. Coffee and caffeine chronologically potentiate the antiamyloidogenic activity of melatonin via inhibition of Aβ oligomerization and modulation of Tau-mediated pathway in N2a/APP cells. Drug Design, Development and Therapy 2014 (accepted in August 2014).
  • Zhang Y, Pan SY*, Zhou SF*, Wang XY, Sun N, Zhu PL, Chu ZS, Yu ZL, & Ko KM. Time and dose relationships between schisandrin B- and Schisandrae fructus oil-induced hepatotoxicity and the associated elevations in hepatic and serum triglyceride levels in mice. Drug Design, Development and Therapy 2014; Volume 2014 (8): 1429—1439.
  • Zhang Z, Zhong X, Ji H, Tang Z, Bai J, Yao M, Hou J, Zheng M, Wood D, Sun J, Zhou SF*, & Liu A. Matrix-induced autologous chondrocyte implantation (MACI) for cartilage repair of the knees in Chinese patients with cartilage defects. Drug Design, Development and Therapy2014 (accepted in August 2014).
  • Zhou QY, Whelan G, Zhou SF, Lane ML, & Vesely DL. Subcutaneous pharmacokinetics of the cardiac hormone vessel dilator.Clinical and Experimental Pharmacology and Physiology2014; 41(8): 565–570. 
  • Zhu Y, Ming Cheng M, Yang Z, Zeng CY, Chen J, Xie Y, Luo SW, Zhang KH, Zhou SF, & Lu NH. Mesenchymal stem cell-based NK4 gene therapy in nude mice bearing gastric cancer xenografts. Drug Design, Development and Therapy 2014 (accepted in August 2014).
  • Bao X, Mao YR, Lin Q, Qiu YH, Chen SZ, Li L, Cates RS, Zhou SF, & Huang DF. Mechanism of Kinect-based virtual reality training for motor functional recovery of upper limbs after subacute stroke. Neural Regeneration Research 2013; 8(31): 2904-2913.
  • Chen XW, Sun J, & Zhou SF*. Protein kinase inhibitors for clinical targeted cancer treatment. Clinical Pharmacology & Biopharmaceutics2013; 2(1): e112.
  • Dawar S, Singh N, Kanwar RK, Kennedy RL, Veedu RN, Zhou SF, Krishnakumar S, Hazra S, Sasidharan S, Duan W, & Kanwar JR. Multifunctional and multitargeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers. Drug Discovery Today 2013; 18(23-24): 1292–1300.
  • He ZX, Yang T, & Zhou SF*. Dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes mellitus: Focus on efficacy, disposition, and safety. Austin Journal of Pharmacology and Therapeutics 2013; 1(1): 3.
  • Jia Z, Liu G, Sun Y, Kakizoe Y, Guan G, Zhang A, Zhou SF& Yang T. mPGES-1-derived PGE2 mediates dehydration natriuresis. American Journal of Physiology - Renal Physiology 2013; 304(2): F214-F221.
  • Kang KF, Wang XW, Chen XW, Kang ZJ, Zhang X, Wilbur RR, Cheng F, & Zhou SF*. Both beclin 1 and nuclear factor-κBp65 are up-regulated in hepatocellular carcinoma. Oncology Letters 2013; 5(6): 1813-1818.
  • Li X, Lu J, Reng H, Chen TJ, Gao L, Di L, Song ZC, Zhang Y, Yang T, Thakur A, Zhou SF, Yin YH,& Chen MW. Combining multiple serum biomarkers in tumor diagnosis: a clinical assessment. Molecular and Clinical Oncology 2013; 1(1): 153-160.
  • Liu C, Liu C, Li J, Yang D, Nabar NR, Zhou SF*,& Ma W. Genetic polymorphisms of 9 non-CODIS short tandem repeat loci in two ethnic minority populations in Southern China. Forensic Science International: Genetics 2013;7: e114-e115.
  • Liu S, Jia Z, Zhou L, Liu Y, Ling H, Zhou SF, Zhang A, Du Y, Guan G,& Yang TX. Nitro-oleic acid protects against adriamycin-induced nephropathy in mice. American Journal of Physiology - Renal Physiology 2013; 305(12): F1533-F1541.DOI: 10.1152/ajprenal.00656.2012.
  • Luo Y, Cha DG, Liu YL, & Zhou SF*. Differential effects of selective and non-selective nitric oxide synthase inhibitors on the blood perfusion of ischemia-reperfused myocardium in dogs. Medical Science MonitorBasic Research 2013; Jun 28;19:181-6. doi: 10.12659/MSMBR.883964.
  • Mao L, Zhou Q, Zhou SF, Wilbur RR, & Li XT. Roles of apolipoprotein E (ApoE) and inducible nitric oxide synthase (iNOS) in inflammation and apoptosis in preeclampsia pathogenesis and progression. PLoS One2013; 8(3): e58168.
  • Persaud-Sharma V & Zhou SF*. Incorporation of new technologies into global pharmacovigilance. Journal of Pharmacovigilance2013; 1(1): e102.
  • Pan SY, Zhou SF*, Gao S,Yu ZL, Zhang SF,Tang MK, Sun JN, Ma DL, Han YF, Fong WF,&Ko KM. New perspectives on how to discover drugs from herbal medicines: CAM’s outstanding contribution to modern therapeutics. Evidence-based Complementary and Alternative Medicine (eCAM) 2013; Volume 2013; article ID: 627375.
  • Qiu JX, He YQ, Wang Y, Xu RL, Qin Y, Shen X, Zhou SF*, &Miao ZF. Plumbagin induces the apoptosis of human tongue carcinoma cells through the mitochondrial-mediated pathway. Medical Science MonitorBasic Research2013;19: 228-236.
  • Shigdar S, Qiao L, Zhou SF, Xiang D, Wang T, Li Y, Lim LY, Kong L, Li L,& Duan W. RNA aptamers targeting cancer stem cell marker CD133. Cancer Letters 2013; March 1;330(1):84-95. doi: 10.1016/j.canlet.2012.11.032.
  • Shigdar S, Macdonald J, O’Connor M, Wang T, Xiang D, Shamaileh HA, Qiao L, Wei MQ, Zhou SF, Zhu Y, Kong L, Bhattacharya S, Li C, & Duan W.Aptamers as theranostic agents: modifications, serum stability and functionalization. Sensors 2013; October10,13(10): 13624-13637.
  • Wang G, Xu L, Gong M, Wilbur RR, Wen P, Zhou SF& Wen J. Effect of somatostatin, ulinastatin and Salvia miltiorrhiza on treatment of severe acute pancreatitis. American Journal of Medical Sciences 2013; November;346(5):371-376. doi: 10.1097/MAJ.0b013e31827aa2bc.
  • Wang G, Xu L, Zhou SF, Gong M, Wen P, Wen J,& Xiao X. Effect of enteral nutrition and ecoimmunonutrition on bacterial translocation and cytokine production in patients with severe acute pancreatitis. Journal of Surgical Research 2013; August;183(2): 592-597.
  • Wang K, Sun J, Zhou SF,Wan C, Qin S, Li C, He L, & Yang L. Prediction of drug-target interactions for drug repositioning only based on genomic expression similarity. PLOS Computational Biology 2013; 9(11): e1003315.
  • Yin JJ, Sharma S, Shumyak SP, Wang ZX,Zhou ZW, Zhang Y, Guo P, Li CZ, Kanwar JR, Yang T, Mohapatra SS, Liu W, Duan W, Wang JC, Li Q, Zhang X, Tan J, Jia L, Liang J, Wei MQ, Li X, & Zhou SF*. Synthesis and biological evaluation of a novel cancer treatment based on folic acid receptor-targeted, β-cyclodextrin-based drug complexes. PLOS One2013: 8(5): e62289. (Highlighted by World Biomedical Frontiers Cancer-2014-5-6).
  • Yin JJ, Zhou ZW, & Zhou SF*. Cyclodextrin-based targeting strategies for tumor treatment. Drug Delivery and Translational Research2013; 3(4): 364-374.DOI 10.1007/s13346-013-0140-4.
  • Zhang SQ, Sawmiller D, Li S, Rezai-Zadeh K, Hou H, Zhou SF, Shytle D, Giunta B, Fernandez F, Mori T, & Tan J. Octyl gallate markedly promotes anti-amyloidogenic processing of APP through estrogen receptor-mediated ADAM10 activation.PLOS One 2013; August 15, 8(8): e71913.doi: 10.1371/journal.pone.0071913.
  • Zhou L, Liu G, Jia Z, Yang KT, Sun Y, Kakizoe Y, Liu M, Zhou SF, Chen R, Yang B, & Yang T.Increased susceptibility of db/db mice to rosiglitazone-induced plasma volume expansion: role of dysregulation of renal water transporters. American Journal of Physiology. Renal Physiology 2013; 305(12): F1491-F1497. DOI: 10.1152/ajprenal.00004.2013.
  • Zhou Q & Zhou SF*. Application of pharmacokinetic modeling approach in development oftherapeutic macromolecules. Clinical Pharmacology & Biopharmaceutics2013;2(1): e111.
  • Zhou Q, Shen J, Zhou G, Shen L, Zhou SF*, & Li X. Effects of magnesium sulfate on heart rate, blood pressure variability and baroreflex sensitivity in preeclamptic rats treated with L-NAME. Hypertension in Pregnancy 2013; 1-10.
  • Zhou SF*. Is pharmacogenomics ready for prime time?Journal of Pharmacogenomics & Pharmacoproteomics2013; 3: e126. doi:10.4172/2153-0645.1000e126.
  • Chen CJ, Zhao ZX, Wang JC, Zhao EY, Gao LY, Zhou SF, Liu XY, Lu WL & Zhang Q. A comparative study of three ternary complexes prepared in different mixing orders of siRNA/redox-responsive hyperbranched poly(amido amine)/hyaluronic acid. International Journal of Nanomedicine 2012; 7: 3837-3849.
  • Chen XW, Sneed KB, Cao CH, Kanwar JR, Chew H,& Zhou SF*. Herb-drug interactions and clinical and mechanistic considerations. Current Drug Metabolism 2012; 13(5): 640-651.
  • Chen XW & Zhou SF*. Can we avoid unfavorable clinical herb-drug interactions?Advances in Pharmacoepidemiology and Drug Safety2012; 1:e105.
  • Chen XW, Yuan MD, Zhang J, Zhou ZW, Li CG,& Zhou SF*. Interaction of herbal compounds with biological targets: a case study with berberine. The Scientific World Journal 2012; article ID 708292, doi: 10.1100/2012/708292.
  • Chen XW, Zhu DJ, Ju YL,& Zhou SF*. Therapeutic effect of transplanting magnetically labeled bone marrow stromal stem cells in a liver injury rat model with 70%-hepatectomy. Medical Science Monitor 2012; 18(10): BR375-382.
  • Chen XW, Liu W,& Zhou SF*. Pharmacogenomics-guided approaches to avoiding adverse drug reactions. Clinical Pharmacology & Biopharmaceutics 2012; 1(3): 1000104.
  • He QL, Chen Y, Qin J, Mo SL, Wei M, Zhang JJ, Li MN, Zou XL, Zhou SF*, Chen XW,& Sun LB. Osthole, a herbal compound, alleviates nucleus pulposus-evoked nociceptive responses through the suppression of overexpression of acid-sensing ion channel 3 (ASIC3) in rat dorsal root ganglion. Medical Science Monitor2012; 18(6): BR229-236.
  • Kanwar JR, Punj V, Sriramoju B, Mohan RR, Zhou SF, Chauhan A,& Kanwar RK. Nanoparticles in the treatment and diagnosis of neurological disorders: Untamed dragon with fire power to heal. Nanomedicine: Nanobiotechnology, Biology, and Medicine 2012; 8(4): 399-414.
  • Lai XS, Wang JY, Nabar NR, Pan SQ, Tang CZ, Huang Y, Hao MF, Yang ZH, Ma C, Zhang J, Chew H, He ZQ, Yang JJ, Su BG, Zhang J, Liang J, Sneed KB,& Zhou SF*. Proteomic response to acupuncture treatment in spontaneously hypertensive rats. PLOS One 2012; 7(9): e44216.
  • Luo Z, Li J, Nabar NR, Lin X, Bai G, Cai J, Zhou SF, Cao C,& Wang J. Efficacy of a therapeutic vaccine using mutated β-amyloid sensitized dendritic cells in Alzheimer’s mice.Journal of Neuroimmune Pharmacology 2012; 7(3): 640-655.
  • Mo SL, Liu WF, Chen YL, Luo HB, Sun LB, Chen XW, Zhou ZW, Sneed KB, Li CG, Du YM, Liang J,& Zhou SF*. Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and virtual screening of the Chinese herbal medicine, Scutellaria Baicalensis (Huangqin, Baikal Skullcap). Combinatorial Chemistry andHigh Throughput Screening2012; 15(1): 36-80.
  • Mo SL, Liu WF, Li CG, Zhou ZW, Luo HB, Chew H, Liang J,& Zhou SF*. Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to Chinese herbal medicine screening. Current Pharmaceutical Biotechnology 2012; 13(8): 1640-1704.
  • Nabar NR, Yuan F, Lin X, Wang L, Bai G, Mayl J, Li Y, Zhou SF, Cai J,&Cao C. Cell therapy: A safe and efficacious therapeutic treatment for Alzheimer’s disease in APP+PS1 mice. PLOS One 2012; 7(12): e49468.
  • Pan SY, Gao SH, Zhou SF, Tang MK, Yu ZL &Ko KM. New perspectives on complementary and alternative medicine: an overview and alternative therapy. Alternative Therapies in Health and Medicine2012; 18(4): 20-36.
  • Persaud-Sharma V & Zhou SF*. Drug repositioning: a faster path to drug discovery. Advances in Pharmacoepidemiology and Drug Safety 2012; 1: 1000e117. Doi: 10.4172/2167-1052.1000e117.
  • Wei M, Nabar NR, Mo SL, Chen YL,  Zhang JJ, He QL, Zou XN, Liu XG, Sun LB,& Zhou SF*. Modification of rat model of sciatica induced by lumber disc herniation and the anti-inflammatory effect of osthole given by epidural catheterization.Pharmacology 2012; 90(5-6): 251-263.
  • Yang LP, Zhou ZW, Chen XW, Li CG, Sneed KB, Liang J,& Zhou SF*. Computational and in vitro studies on the inhibitory effects of herbal compounds on human cytochrome P450 1A2. Xenobiotica 2012; March, 42(3): 238-255.doi: 10.3109/00498254.2011.610833.
  • Yang TY, Wang YG, Li ZQ, Dai WB, Yin J, Liang L, Ying X, Zhou SF, Wang JC, Zhang X,&Zhang Q. Targeted delivery of a combination therapy consisting of combretastatin A4 and low-dose doxorubicin against tumor neovasculature. Nanomedicine: Nanobiotechnology, Biology, and Medicine2012; 8(1): 81-92.
  • Zhang J & Zhou SF*. Can we discover “really safe and effective” anticancer drugs?Advances in Pharmacoepidemiology and Drug Safety2012; 1: 5.
  • Zhou YX, Mo SL, Wang RH, Liu WF, Liu JC, Wang JQ, He J, Zhang H, Guan ZZ, Zhou SF,& Yu YN. Corn baked by burning coal triggered overexpression of osteopontin in hepatocytes of rats following fluorosis. Toxicology and Industrial Health 2012; 28(3): 195-202.
  • Zhou ZW, Xie XL, Zhou SF& Li CG. Mechanism of reversal of high glucose-induced endothelial nitric oxide synthase uncoupling by tanshinone IIA in human endothelial cell line EA.hy926. European Journal of Pharmacology 2012; 697(1-3): 97-105.
  • Chang J, Jiang Z, Zhang H, Zhu H, Zhou SF& Yu XQ.NADPH oxidase-dependent formation of reactive oxygen species contributes to angiotensin II-induced epithelial-mesenchymal transition in rat peritoneal mesothelial cells. International Journal of Molecular Medicine 2011; 28(3):405-412.
  • Chen XW, Serag ES, Sneed KB& Zhou SF*. Clinical herbal interactions with conventional drugs: from molecules to maladies. Current Medicinal Chemistry 2011; 18(31): 4836-4850.
  • Chen XW, Serag ES, Sneed KB& Zhou SF*. Herbal bioactivation, molecular targets and the toxicity relevance. Chemico-Biological Interactions2011; 192(3): 161-176.
  • Chen XW, Sneed KB & Zhou SF*. Pharmacokinetic profiles of anticancer herbal medicines in humans and the clinical implications. Current Medicinal Chemistry 2011, 18(21): 3190-3210.
  • Dai ZB, Cui GH, Zhou SF*, Zhang XN& Huang LQ. Cloning and characterization of a novel 3-hydroxy-3-methylglutaryl coenzyme A reductase gene from Salvia miltiorrhiza and its homologous overexpression increases diterpenoid tanshinone accumulation. Journal of Plant Physiology 2011; 168(2): 148-157.
  • Di YM, Zhou ZW, Li CG& Zhou SF*. Current and future therapeutic targets for rheumatoid arthritis. Anti-inflammatory and Anti-Allergy Agents in Medicinal Chemistry 2011; 10(2): 92-120.
  • Dou X, Hu H, Ju Y, Liu Y, Kang K, Zhou SF& Chen W. Concurrent nephrotic syndrome and acute renal failure caused by chronic lymphocytic leukemia (CLL): a case report and literature review. Diagnostic Pathology2011; 6: 99.
  • He SM, Chan E& Zhou SF*. ADME properties of herbal medicines in humans: evidence, challenges and strategies. Current Pharmaceutical Design 2011; 17(4):357-407.
  • He SM, Li RS, Kanwar JR,& Zhou SF*. Structural and functional properties of human multidrug resistance protein 1 (MRP1/ABCC1). Current Medicinal Chemistry 2011;18(3): 439-481.
  • He SM, Xing F, Sui H, Wu Y, Wang Y, Wang D, Chen G, Kong Z,& Zhou SF*. Determination of CA-125 levels in the serum, cervical and vaginal secretions, and endometrium in Chinese women with precancerous disease or endometrial cancer. Medical Science Monitor2011; 17(11):CR618-625.
  • He SM, Zhou ZW, Li XT,& Zhou SF*. Clinical drugs undergoing polymorphic metabolism by human cytochrome P450 2C9 and the implication in drug development. Current Medicinal Chemistry 2011; 18(5): 667-713.
  • Kanwar JR, Zhou SF, Gurudevan SG, Barrow CJ,& Kanwar RK. Toll like receptors play a role in general immunity, eye infection and inflammation: TLRs for nanodelivery. Journal of Clinical & Cellular Immunology2011; 2(4): 1-10.
  • Li ZJ, An X, Mao HP, Wei X, Chen JH, Yang X, Zhou SF, Li ZB,& Yu XQ. Association between depression and malnutrition-inflammation complex syndrome in patients with continuous ambulatory peritoneal dialysis. International Urology and Nephrology 2011; 43(3):875-882.
  • Lian H, Ma D, Zhou SF*,& Li XT. Knowledge and use of folic acid for birth defect prevention among young women in Shanghai of China. Medical Science Monitor 2011; 17(12):PH87-92.
  • Luo Y, Pan YZ, Zeng C, Li GL, Lei XM, Liu Z,& Zhou SF*. Altered serum creatine kinase level and cardiac function in ischemia-reperfusion injury during percutaneous coronary intervention. Medical Science Monitor 2011; 17(9): CR474-479.
  • Sui H, Zhou L, Wang Y, Fan Z, Zhou SF*& Li Q. COX-2 Contributes to P-glycoprotein-mediated multidrug resistance via JNK signal transduction pathway in HCT8/V cells. Carcinogenesis 2011; 32 (5): 667-675.
  • Wang B, Hu JJ, Yan CF, Su HH, Ding JC, Guo YY, Ye N, Huang SQ, Zhang XZ & Zhou SF*. Characterization of human cytomegalovirus UL145 and UL136 genes in low-passage clinical isolates from infected Chinese infants. Medical Science Monitor 2011; 17(8): CR423-431.
  • Wang CF, Chen XJ, Zhou SF*,& Li XT. Impaired fetal adrenal function in intrahepatic cholestasis of pregnancy. Medical Science Monitor 2011; 17(5): CR 265 - 271.
  • Wang LL, Liu YH, Meng LL, Li CG,& Zhou SF*. Phenotype prediction of non-synonymous single nucleotide polymorphisms in human ATP-binding cassette (ABC) transporter genes. Basic and Clinical Pharmacology and Toxicology 2011; 108(2): 94-114.
  • Xiong Y,Zhou SF, Lou Y, Guo Q, Hu R, Ma D,& Li XT. Alternations of maternal and cord plasma haemostasis in preeclampsia before and after delivery.Hypertension in Pregnancy 2011; 30(3): 347-358.
  • Zhou J, Guo L, Zhang J, Zhou SF, Yang G, Zhao M,&Huang L. Effects of LaCl3 on photosynthesis and the accumulation of tanshinones and salvianolic acids in Salvia miltiorrhiza seedlings. Journal of Rare Earths 2011; 29(5): 494-498.
  • Cheng Y, Hu R, Jin H, Ma K, Zhou SF, Cheng H, Ma D& Li X. Effect of 14-3-3 tau protein on differentiation in BeWo choriocarcinoma cells. Placenta 2010; 31(1): 60-66.
  • He SM, Li CG, Liu JP, Chan E, Duan W, & Zhou SF*. Disposition pathways and pharmacokinetics of herbal medicines in humans.Current Medicinal Chemistry 2010; 17(33): 4072-4113.
  • He SM, Yang AK, Li XT, Du YM& Zhou SF*. Effects of herbal products on the metabolism and transport of anti-cancer agents.Expert Opinions on Drug Metabolism and Toxicology 2010; 6(10): 1195-1213.
  • Liu JP & Zhou SF*. 2009 Nobel Prize in Physiology and Medicine awarded on an enzyme in cancer.Clinical and Experimental Pharmacology and Physiology 2010; 37(1): 75-77.
  • Liu JP, Chen SM, Cong YS, Nicholls C,Zhou SF, Tao ZZ & Li H.Regulation of telomerase activity by apparently opposing elements.Aging Research Reviews 2010; 9(3): 245-256.
  • Liu JP, Tang Y,Zhou SF, Toh BH, McLean C& Li H. Cholesterol involvement in the pathogenesis of neurodegenerative diseases.Molecular and Cellular Neuroscience2010; 43(1): 33-42.
  • Liu YH, Di YM, Zhou ZW, Mo SL& Zhou SF*. Multidrug resistance associated proteins and implications in drug development. Clinical and Experimental Pharmacology and Physiology 2010; 37(1): 115-120.
  • Luo Y, Cha DG, Liu YL & Zhou SF*. Coronary microcirculation changes during myocardial stunning in dogs. Cardiology 2010; 117(1): 68-74.
  • Ma Y, Cheng Y, Wang J, Cheng H, Zhou SF& Li XT. The changes of visfatin in serum and its expression in fat and placental tissue in pregnant women with gestational diabetes. Diabetes in Research and Clinical Practice 2010; 90(1): 60-65.
  • Matthews L, Kanwar RK, Zhou SF, Bawa R, Punj V& Kanwar JR. Applications of nanomedicine in antibacterial medical therapeutics and diagnostics. TheOpen Tropical Medicine Journal2010; 3(1): 1-9.
  • Mengesha A, Wei JZ, Zhou SF& Wei M. Clostridial spores to treat solid tumours – potential for a new therapeutic modality. Current Gene Therapy 2010; 10(1): 15-26.
  • Peng T, Li XT, Zhou SF, Xiong Y, Kang Y& Cheng HD. Transcutaneous electrical nerve stimulation on acupoints relieves labor pain: a non-randomized controlled study. Chinese Journal of Integrative Medicine 2010; 16(3): 234-238.
  • Peng T, Wang L, Zhou SF*& Li XT. Mutations of the GATA4 and NKX2.5 genes in Chinese paediatric patients with congenital heart disease. Genetica 2010; 138(11-12): 1231-1240.
  • Wang LL, Yang AK, He SM, Liang J, Zhou ZW, Li Y& Zhou SF*. Identification of the molecular targets associated with ethanol toxicity and implications in drug development. Current Pharmaceutical Design 2010; 16(11): 1313-1355.
  • Wang LL, Yang AK, Li Y, Liu JP & Zhou SF*. Phenotype prediction of deleterious non-synonymous single nucleotide polymorphisms in human alcohol metabolism-related genes: A bioinformatics study. Alcohol 2010; 44(5): 425-438.
  • Wen Q, Zhao H, Zhou SF, Li XY, Luo N& Yu XQ. Urinary proteins from patients with nephrotic syndrome alter the signaling proteins regulating epithelial–mesenchymal transition. Nephrology 2010; 15(1): 63-74.
  • Xiong Y, Zhou Q, Jiang F, Zhou SF, Lou Y, Guo Q, Liang W, Kong D, Ma D& Li XT. Changes of plasma and placental tissue factor pathway inhibitor-2 in women with preeclampsia and normal pregnancy. Thrombosis Research 2010; 125(6): e317-322.
  • Yang AK, He SM, Liu L, Liu JP, Wei M& Zhou SF*. Herbal interactions with anticancer drugs: mechanistic and clinical considerations. Current Medicinal Chemistry 2010; 17(16): 1635-1678.
  • Yang AK, Zhou ZW, Wei M, Liu JP& Zhou SF*. Modulators of multidrug resistance proteins in the management of anticancer and antimicrobial drug resistance and the treatment of inflammatory diseases.Current Topics in Medicinal Chemistry 2010; 10(17): 1732-1756.
  • Zhou SF*, Wang B, Yang LP&Liu JP. Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2. Drug Metabolism Reviews2010; 42(2): 268-354.
  • Zhou SF*, Zhou ZW& Huang M. Polymorphism of human cytochrome P450 2C9 and functional relevance. Toxicology 2010; 278(2): 165-188.
  • Zhou SF*, Zhou ZW, Huang M& Lu YB. Pharmacokinetics and disposition of plant natural products in humans and the clinical and toxicological implications. Current Organic Chemistry 2010; 14(16): 1833-1868.
  • Zhu LJ, Yang X, Li XY, Liu QH, Tang XQ,Zhou SF, Kong QY, Axelsson J& Yu XQ. Suppression of tumor necrosis factor receptor associated factor (TRAF)-2 attenuates the proinflammatory and proliferative effect of aggregated IgG on rat renal mesangial cells.Cytokine 2010; 49(2): 201-208.
  • Chen W, Chen W, Wang H, Dong X,Liu Q, Mao H, Tan J, Lin J, Zhou F, Luo N, He H, Johnson RJ, Zhou SF& Yu XQ.  Prevalence and risk factors associated with chronic kidney disease in adult population in Southern China. Nephrology Dialysis Transplantation 2009; 24(4): 1205-1212.
  • Di YM, Chan E, Wei M, Liu JP& Zhou SF*. Prediction of deleterious non-synonymous single nucleotide polymorphisms of human uridine diphosphate glucuronosyltransferase. AAPS Journal 2009; 11(3): 469-480.
  • Di YM, Chow WD, Yang LP& Zhou SF*. Structure, function, regulation and polymorphism of human cytochrome P450 2A6.Current Drug Metabolism 2009; 10(7): 754-780.
  • Fu YH, Lin QX, Li XH, Fei HW, Shan ZX, Huang XZ, Liu XY, Yang M, Lin SG, Zhou SF*, Zhang YY&Yu XY.Ade novo rat model of chronic heart failure following myocardial infarction.Methods & Findings in Experimental & Clinical Pharmacology 2009; 31(6): 1-7.
  • Guo QS, Qin SY, Zhou SF*, He L, Ma D, Zhang YP, Xiong Y, Peng T, Cheng Y & Li XT.Unbalanced translocation in an adult patient with premature ovarian failure and mental retardation detected by spectral karyotyping and array-comparative genomic hybridization (Erratum inEur J Clin Invest 2009;39(12):1114). European Journal of Clinical Investigations 2009; 39(8): 3729-3737.
  • Katik I, Mackenzie-Kludas C, Nicholls C, Jiang F, Zhou SF, Li H& Liu JP. Activin inhibits telomerase activity in cancer. Biochemical & Biophysical Research Communications2009; 389(4): 668-672.
  • Lai XS, Yang LP, Li XT, Liu JP, Zhou ZW& Zhou SF*. Human cytochrome P450 2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Current Drug Metabolism 2009; 10(9): 1009-1047.
  • Lai XS, Zhang G, Huang Y, Tng CZ, Yang J, Wang S & Zhou SF*. A cerebral functional imaging study by positron emission tomography in healthy volunteers receiving true or sham acupuncture needling. Neuroscience Letters 2009; 452(2): 194-199.
  • Li CG, Sheng SJ, Pang E, May B, Marriot P, Zhou SF, Story DF &Xue CCL. Cultivar variations of Australian-grown Danshen (Salvia miltiorrhiza): Bioactive markers and root yields. Chemical Biodiversity 2009; 6(2): 170-181.
  • Liu YH, Li CG& Zhou SF*. Prediction of deleterious functional effects of non-synonymous single nucleotide polymorphisms in human nuclear receptors using a bioinformatics approach. Drug Metabolism Letters 2009; 3(4): 242-286.
  • Luo Y, Li GL, Pan YZ& Zhou SF*. Determinants and prognostic implications of reperfusion injury duringprimarypercutaneous coronary intervention in Chinese patients with acute myocardial infarction. Clinical Cardiology 2009; 32(3): 148-153.
  • Mo SL, Liu YH& Zhou SF*.Structure, function, regulation and polymorphism of human cytochrome P450 2B6. Current Drug Metabolism 2009; 10(7): 730-753.
  • Mo SL, Zhou ZW, Yang LP, Wei M& Zhou SF*. New insights into the structural features and the functional relevance of human cytochrome P450 2C9. Part I. Current Drug Metabolism 2009; 10(10): 1075-1126.
  • Mo SL, Zhou ZW, Yang LP, Wei M & Zhou SF*. New insights into the structural features and the functional relevance of human cytochrome P450 2C9. Part II. Current Drug Metabolism 2009; 10(10): 1127-1150.
  • Qu YC, Du YM, Wu SL, Chen QX, Wu HL & Zhou SF*.  Activated nuclear factor-kB and increased tumor necrosis factor-a in atrial tissue of atrial fibrillation. Scandinavian Cardiovascular Journal2009; 43(2): 292-297.
  • Wang B& Zhou SF*. Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implication in drug development. Current Medicinal Chemistry 2009; 16(31): 4066-4218.
  • Wang B, Wang J, Huang SQ, Su HH& Zhou SF*. Genetic polymorphism of the human cytochrome P450 2C9 gene and the clinical significance. Current Drug Metabolism2009; 10(7): 781-834.
  • Wang B, Zhang XZ, Yang LP, Huang SQ, Bartlam B& Zhou SF*. New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. Drug Metabolism Reviews 2009; 41(4): 573-643.
  • Wang LL, Li Y & Zhou SF*. A bioinformatics approach for the phenotype prediction of non-synonymous single nucleotide polymorphisms in human cytochrome P450s. Drug Metabolism and Disposition 2009; 37(5): 977-991.
  • Wang LL, Li Y & Zhou SF*. Prediction of deleterious non-synonymous single nucleotide polymorphisms of genes related to ethanol-induced toxicity. Toxicology Letters2009; 187(4): 99-114.
  • Wang LL, Zhang Z, Li Q, Yang R, Pei X, Xu Y, Wang J, Li Y & Zhou SF*. Ethanol exposure induces differential microRNA and target gene expression and teratogenic effects which can be suppressed by folic acid supplementation. Human Reproduction 2009; 24(3): 562-579.
  • Wang XD, Li JL, Su QB, Guan S, Chen J, Du J, He YW, Zeng J, Zhang JX, Chen X, Liu YH, Huang M& Zhou SF*.  Impact of the haplotypes of the human pregnane X receptor gene on the basal and St John’s wort-induced activity of cytochrome P450 3A4 enzyme.British Journal of Clinical Pharmacology2009; 67(2): 255-261.
  • Wu J, Yang X, Zhang YF, Zhou SF, Zhang R, Dong XQ, Fan JJ, Liu M & Yu XQ. Angiotensin II upregulates Toll-like receptor 4 and enhances lipopolysaccharide-induced CD40 expression through nuclear factor-κB activation in rat peritoneal mesothelial cells. Inflammation Research 2009; 58(8): 473-482.
  • Xu J, Liu XS, Zhou SF& Wei M. Combination ofimmunotherapy with anaerobic bacteria for immunogene therapy of solid tumours.Gene Therapy and Molecular Biology 2009; 13(1): 36-52.
  • Yau WP, Zhou SF& Chan E.Mechanism-based enterohepatic circulation model ofmycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients. The Journal of Clinical Pharmacology 2009; 49(6): 684-699.
  • Zhang H, Jiang Z, Chang J, Li X, Zhu H,Lan HY, Zhou SF& Yu XQ.Role of NAD(P)H oxidase in transforming growth factor-b1 (TGF-β1)-induced monocyte chemoattractant protein-1 and interleukin-6 expression in rat renal tubular epithelial cells.Nephrology 2009; 14(3): 302-310.
  • Zhang W, Smith A, Liu JP, Cheung NS, Zhou SF, Liu K, Li QT & Duan W. GSK3b modulates PACAP-induced neuritogenesis in PC12 cells by acting downstream of RAP1 in a caveolae-dependent manner. CellularSignalling 2009; 21(2): 237-245.
  • Zhou SF*, Liu JP& Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews 2009; 41(1): 89-295.
  • Zhou SF*, Liu JP& Lai XS. Substrate specificity, inhibition and regulation of human cytochrome P450 2D6 and implications in drug development. Current Medicinal Chemistry 2009; 16(21): 2661-2805.
  • Zhou SF*, Yang LP, Zhou ZW, Liu YH& Chan E. Insights into the substrate specificity, inhibitors, and polymorphism and the clinical impact of human cytochrome P450 1A2. AAPS Journal 2009; 11(3): 481-494.
  • Zhou SF*, Yang LP, Zhou ZW, Xue CC, Lai XS& Duan W. Insights into the structure, function, and regulation of human cytochrome P450 1A2. Current Drug Metabolism 2009; 10(7): 713-729.
  • Zhou SF*, Zhou ZW, Yang LP&Cai JP. Substrates, inducers, inhibitors and structure-activity relationships of human cytochrome P450 2C9 and implications in drug development. Current Medicinal Chemistry 2009; 16(27): 3480-3675.
  • Zhou SF*. Polymorphism of human cytochrome P450 2D6 and its clinical significance. Part I. Clinical Pharmacokinetics2009; 48(11): 689-723.
  • Zhou SF*. Polymorphism of human cytochrome P450 2D6 and its clinical significance. Part II. Clinical Pharmacokinetics2009; 48(12): 761-804.
  • Zhou SF*. The future of Traditional Chinese Medicine.Australian Journal of Acupuncture and Chinese Medicine 2009; 4(1): 23-24.
  • Zhou ZW& Zhou SF*. Application of mechanism-based CYP inhibition for predicting drug-drug interactions. Expert Opinion on Drug Metabolism and Toxicology 2009; 5(6): 579-605.
  • Zhu LJ, Yang X, Ji Y, Chen W, Guan W, Zhou SF& Yu XQ. Up-regulated renal expression of TNF-a signaling adapter proteins in lupus glomerulonephritis. Lupus 2009; 18(2): 116-127.
  • Bi HC, Zuo Z, Chen X, Xu CS, Wen YY, Sun HY, Zhao LZ, Pan Y, Deng Y, Liu PQ, Gu LQ, Zhou SF*& Huang M. Preclinical factors affecting the pharmacokinetic behaviors of tanshinone IIA, an investigational new drug isolated from Salvia miltiorrhiza for treatment of ischemic heart diseases.  Xenobiotica 2008; 38(2): 185-222.
  • Cao HX, Li M, Nie J, Wang W, Zhou SF&Yu XQ.Human leukocyte antigen DRB1 alleles predict risk and disease progression of immunoglobulin A nephropathy in Han Chinese.American Journal of Nephrology 2008; 28(4): 684-691.
  • Cheng MB, Wang JC, Li YH, Liu XY, Zhang X, Chen DW, Zhou SF&  Zhang Q. Characterization of water-in-oil microemulsion for oral delivery of earthworm fibrinolytic enzyme. Journal of Controlled Release 2008; 129(1): 41-48.
  • Deng Y, Bi HC, Zhao LZ, He F, Liu YQ, Yu JJ, Ou ZM, Ding L, Chen X, Huang ZY, Huang M& Zhou SF*.Induction of cytochrome P450s by terpene trilactones and flavonoids of the Ginkgo biloba extract EGb 761 in rats. Xenobiotica 2008; 38(5):465-481.
  • Deng Y, Bi HC, Zhao LZ, Wang XD, Chen J, Ou ZM, Ding L, Xu LJ, Guan S, Chen X, Huang M & Zhou SF*. Induction of cytochrome P450 3A by the Ginkgo biloba extract and bilobalides in human and rat primary hepatocytes. Drug Metabolism Letters2008; 2(1): 60-66.
  • Di YM, Li CG, Xue CCL& Zhou SF*. Clinical drugs that interact with St John’s wort and implication in drug development. Current Pharmaceutical Design 2008; 14(17): 1723-1742.
  • Huang Z, Wen Q, Zhou SF& Yu XQ. Differential chemokine expression in tubular cellsin response to urinary proteins from patients with nephrotic syndrome. Cytokine 2008; 42(2): 222-233.
  • Li JL, Wang XD, Wang CX, Fu Q, Liu LS, Huang M& Zhou SF*. Rapid and simultaneous determination of tacrolimus (FK506) and diltiazem in human whole blood by liquid chromatography-tandem mass spectrometry: Application to a clinical drug-drug interaction study.  Journal of Chromatography B: Analytical Technologies in Biomedical and Life Sciences 2008; 867(1):111-118.
  • Li XX, Zhou ZW& Zhou SF*. Role of P-glycoprotein in the transport of tanshinone I, one active triterpenoid from Salvia miltiorrhiza. Drug Metabolism Letters 2008; 2(3): 223-230.
  • Lim WG, Chen X, Liu JP, Tan BJ, Zhou SF, Smith A,Lees N, Hou L, Gu F, Yu XY, Du Y, Smith D,Verma C, Liu K & Duan W. The C-terminus of PRK2/PKNg is required for optimal activation by RhoA in a GTP dependent manner. Archives of Biochemistry and Biophysics2008; 479(2): 170-179.
  • Lindsay J, Wang LL, Li Y& Zhou SF*. Structure, function and regulation of human cytosolic sulfotransferases. Current Drug Metabolism 2008; 9(2): 99-105.
  • Liu W, Liu P, Tao S, Deng Y, Li X, Lan T, Zhang X, Guo F, Huang W, Chen F, Huang H & Zhou SF*.Berberine inhibits aldose reductase and oxidative stress in rat mesangial cells cultured under high glucose. Archives in Biochemistry and Biophysics 2008; 475(2): 128-134.
  • Lu JL, Wang JC, Zhao SX, Liu XY, Zhao H, Zhang X, Zhou SF& Zhang Q. Self-microemulsifying drug delivery system (SMEDDS) improves anticancer effect of oral 9-nitrocamptothecin on human cancer xenografts in nude mice. European Journal of Pharmaceutics & Biopharmaceutics 2008; 69(3): 899-907.
  • Luo B, Huang F, Liu Q, Li X, Chen W, Zhou SF& Yu XQ. Identification of apolipoprotein E Guangzhou (arginine150 proline), a new variant associated with lipoprotein glomerulopathy.American Journal of Nephrology 2008; 28(2): 347-353.
  • Pan Y, Bi HC, Zhong GP,Chen X, Zuo Z, Gu LQ, Liu PQ, Huang ZY, Zhou SF*&Huang M. Pharmacokinetic characterization of hydroxylpropyl-b-cyclodextrin-included complex of cryptotanshinone, an investigational cardiovascular drug purified from Danshen (Salvia miltiorrhiza).  Xenobiotica 2008; 38(4): 382-398.
  • Sandanaraj E, Jada SR, Shu X, Lim R, Lee SC, Zhou Q, Zhou SF, Goh BC & Chowbay B. Influence of UGT1A9 intronic I399C>T polymorphism on SN-38 glucuronidation in Asian cancer patients. ThePharmacogenomics Journal2008; 8(3): 174-185.
  • Shen Y, Li CG, Zhou SF, Pang ECK, Story DF& Xue CCL. Chemistry and bioactivity of Flos Magnoliae, a commonly used Chinese herbal medicine for management of rhinitis and sinusitis.  Current Medicinal Chemistry 2008; 15(16): 1616-1627.
  • Su QB, He F, Wang XD, Guan S, Wang LY, Lu YJ, Gu LQ, Huang ZS, Chen X, Huang M & Zhou SF*. Biotransformation and pharmacokinetics of the novel anticancer drug, SYUIQ-5, in the rat. Investigational New Drugs 2008; 26(2): 119-137.
  • Wang XD, Deng XY, Chen J, Li JL, Chen X, Zhao LZ, Lu Y, Chowbay B, Su QB, Huang M & Zhou SF*.Single nucleotide polymorphisms of the pregnane X receptor gene in Han Chinese and a comparison with other ethnic populations. Pharmacology 2008; 81(4): 350-354.
  • Weier N, He SM, Li XT, Wang LL& Zhou SF*. Placental drug disposition and the clinical implications. Current Drug Metabolism 2008; 9(2): 106-121.
  • Yu XQ, Xue CCL, Zhou ZW, Li CG & Zhou SF*. Tanshinone IIB, a primary active constituent from Salvia Miltiorrhiza, exerts neuronprotective effect via inhibition of neuronal apoptosis. Phytotherapy Research 2008; 22(6): 846-850.
  • Yu XQ, Zhou ZW, Du YM, Liang J, CCL Xue, Li CG& Zhou SF*.  In vitro and in vivo neuroprotective effect of glabridin, a major active isoflavan from Glycyrrhiza glabra (Licorice). Life Sciences 2008; 82(1-2): 68-78.
  • Zhang R, Yang X,Wu J,Peng W,Zhou SF& Yu XQ.  Upregulation of rat renal cortical organic anion transporters (OAT1 and OAT3) in response to ischemia-reperfusion injury. American Journal of Nephrology 2008; 28(5): 772-783.
  • Zhou SF*& Lai XS. An update on clinical drug interactions with the herbal anti-depressant St. John’s wort. Current Drug Metabolism 2008; 9(5): 394-409.
  • Zhou SF*&CC Xue. Acupuncture as an adjunct to exercise based physiotherapy does not improve the pain of knee osteoarthritis. Australian Journal of AcupunctureandChinese Medicine 2008; 3(1): 55-57.
  • Zhou SF*, Di YM, Chan E, Du YM, Chow VD, Xue CC, Lai X, Wang JC, Li CG, Tian M& Duan W. Clinical pharmacogenetics and potential application in personalized medicine. Current Drug Metabolism 2008; 9(8): 738-784.
  • Zhou SF*, Wang LL, Xue CCL, Duan W, Li CG& Li Y. Substrates and inhibitors of multidrug resistance associated proteins and the implications in drug development. Current Medicinal Chemistry 2008; 15(20): 1981-2039.
  • Zhou SF*.  Structure, function and regulation of P-glycoprotein. Xenobiotica2008; 38(7-8): 802-832.
  • Zhou SF*. Drugs behave as substrates, inducers and inhibitors of cytochrome P450 3A4. Current Drug Metabolism 2008; 9(4): 310-322.
  • Zhou SF*. Pharmacogenetics of human multidrug resistance associated proteins. Current Pharmacogenomics & Personalized Medicine(formerly ‘Current Pharmacogenomics’)2008; 6(2): 134-149.
  • Zhou SF*. Potential strategies for minimizing mechanism-based inhibition of cytochrome P450 3A4.Current Pharmaceutical Design 2008; 14(10): 990-1000.
  • Zhou SF*. Role of multidrug resistance associated proteins in drug development. Drug Discoveries& Therapeutics 2008: 2(6): 305-332.
  • Zhou SF*, Chowbay B& CCL Xue. Pharmacogenetics of oxazaphosphorines and its clinical implications. Current Pharmacogenomics(presently ‘Current Pharmacogenomics and Personalized Medicine’) 2007; 5(2): 143-156.
  • Cao J, Chen X, Liang J, Yu XQ, Duan W, Chen E, Sheu FS, Xu AL, Yu XY, Wen JY, Huang M& Zhou SF*. Role of P-glycoprotein in the intestinal absorption of glabridin, an active flavonoid extracted from the root of Glycyrrhiza glabra(licorice). Drug Metabolism and Disposition 2007; 35(4): 539-553.
  • Chen X, Zhou ZW, Xue CCL, Li XX& Zhou SF*. Role of P-glycoprotein in restricting the brain penetration of tanshinone IIA, a major active constituent from the root of Salvia miltiorrhiza Bunge, across the blood-brain barrier. Xenobiotica 2007; 37(6): 635-678.
  • Guan S, Bi HC, Pan Y, Chen X, Li CG, Xue CC, Huang M& Zhou SF*. Determination of cryptotanshinone, a major active component in Salvia miltiorrhiza (Danshen), in Caco-2 monolayers by high performance liquid chromatography with ultraviolet detection. Chromatographia 2007; 66(7-8): 577-582.
  • Hu R, Jin H, Zhou SF, Yang P& Li XT.Proteomic analysis of hypoxia-induced responses in the syncytialization of human placental cell Line BeWo. Placenta2007; 28(5-6): 399-407.
  • Hu ZP, Yang XX, Chen X, Cao J, Chan E, Duan W, Huang M, Yu XQ, Wen JY& Zhou SF*. A mechanistic study on altered pharmacokinetics of CPT-11 by St John’s Wort. Current Drug Metabolism 2007; 8(2): 157-171.
  • Hu ZP,Yang XX, Chen X, Chan E, Duan W& Zhou SF*. Simultaneous determination of irinotecan (CPT-11) and SN-38 in tissue culture media and cancer cells by high performance liquid chromatography: application to cellular metabolism and accumulation studies. Journal of Chromatography B: Analytical Technologies in Biomedical & Life Sciences 2007; 850(1): 575-580.
  • Huang H, Liu P, Liu W, Tao S, Zhou ZW, Hei Z, CCL Xue, Li CG, Huang M & Zhou SF*.Effect of a compound herbal formula consisting of Hirudo medicinalis (leech), Rheum rhaponticum (rhubarb, Dahuang), and Cinnamomum cassia (Chinese cassia bark) on diet-induced atherosclerosis in rabbits. Australian Journal of Acupuncture and Chinese Medicine 2007; 2(2): 3-9.
  • Jada SR, Shu XC, Liu YY, Xiang XQ, Suman L, Zhou SF, Ooi LL& Chowbay B. Pharmacogenetics of SLCO1B1: Haplotypes, htSNPs and hepatic expression in three distinct Asian populations. European Journal of Clinical Pharmacology 2007; 63(4): 555-563.
  • Li CG, Yang LP, & Zhou SF. Interactions between Chinese herbal medicines and drugs. Australian Journal of Acupuncture and Chinese Medicine 2007; 2(1): 17-24.
  • Liang J, Huang M, Duan W, Yu XQ& Zhou SF*. Design of new oxazaphosphorine anticancer drugs. Current Pharmaceutical Design 2007; 13(9): 963-978.
  • Su QB, He F, Guan S, Lu YJ, Gu LQ, Huang ZS, Chen X, Huang M, Li CG, Chowbay B & Zhou SF*.High performance liquid chromatography with ultraviolet detection for the determination of SYUIQ-5, a novel telomerase inhibitor for cancer therapy: Application to an enzyme kinetic study in rat liver microsomes. Journal of Chromatography B: Analytical Technologies in Biomedical and Life Sciences 2007; 854(1-2): 332-337.
  • Sun HY, Guan S, Bi HC, Su QB, Huang WL, Chowbay B, Huang M, Chen X, Li CG& Zhou SF*.Determination of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase, in human Caco-2 monolayers by high performance liquid chromatography with ultraviolet detection: Application to a trans-epithelial transport study. Journal of Chromatography B: Analytical Technologies in Biomedical and Life Sciences 2007; 854(1-2): 320-327.
  • Wang B, He F, Yu L, Huang M & Zhou SF*.Effect of recombinant human thymosin-a1, an immuno-modulating peptide with 28 amino acids, on the activity of cytochrome P450s. Drug Metabolism Letters 2007; 1(3): 199-204.
  • Wang XD, Chan E, Chen X, Liao XX, Tang C, Zhou ZW, Huang M& Zhou SF*. Simultaneous and rapid quantitation of benazepril and benazeprilat in human plasma by high performance liquid chromatography with ultraviolet detection.  Journal of Pharmaceutical and Biomedical Analysis 2007; 44(1): 224-230.
  • Wang XD, Li JL, Deng XY, Lu Y, Su QB, Zhao LZ, Zuo Z, Chen X, JX Zhang, Chan E, Chowbay B, Huang M, Xue CCL & Zhou SF*. A pharmacogenetic study of pregnane X receptor (NR1I2) in Han Chinese. Current Drug Metabolism 2007: 8(8): 778-786.
  • Wang XD, Li JL, Lu Y, Chen X, Huang M, Chowbay B& Zhou SF*. Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to aclinical herb-drug interaction study. Journal of Chromatography B: Analytical Technologies in Biomedical and Life Sciences 2007; 852(1-2): 534-544.
  • Yau WP, Vathsala A, Lou HX, Zhou SF& Chan E. Simple reversed-phase liquid chromatographic assay for simultaneous quantification of free mycophenolic acid and its glucuronide metabolite in human plasma. Journal of Chromatography B: Analytical Technologies in Biomedical & Life Sciences 2007; 846(1-2):313-318.
  • Yu XQ, Xue CCL, Wang GJ& Zhou SF*.  Multidrug resistance associated proteins and their role in determining pharmacokinetics and pharmacodynamics of drugs. Current Drug Metabolism 2007; 6(7): 787-802.
  • Yu XY, Lin SG, Chen X, Liang J, Duan W & Zhou SF*. Role of ATP-binding cassette drug transporters in the intestinal absorption of tanshinone IIB, one of the major active diterpenoids from the root of Salvia miltiorrhiza. Xenobiotica 2007; 37(4): 375-415.
  • Yu XY, Lin SG, Chen X, Zhou ZW, Chan E, Chowbay B, Liang J, Duan W, Wen JY, Cao J& Zhou SF*. Transport of cryptotanshinone, a major active triterpenoid in Salvia miltiorrhiza Bunge widely used in the treatment of stroke and Alzheimer’s disease, across the blood-brain barrier.CurrentDrug Metabolism2007; 8(4): 365-378.
  • Yu XY, Lin SG, Wang XM, Liu Y, Zhang B, Lin QX, Yang M& Zhou SF*. Evidence for coexistence of three b-adrenoceptor subtypes in human peripheral lymphocytes. Clinical Pharmacology & Therapeutics 2007; 81(5): 654-658.
  • Yu XY, Lin SG, Zhou ZW, Chen X, Liang J, Duan W, Yu XQ,  Wen JY, Chowbay B, Li CG, Sheu FS, Chan E & Zhou SF*. Tanshinone IIB, a primary active constituent from Salvia Miltiorrhiza, exhibits neuro-protective activity in experimentally stroked rats. Neuroscience Letters 2007; 417(3): 261-265.
  • Yu XY, Lin SG, Zhou ZW, Chen X, Liang J, Huang M, Duan W & Zhou SF*. Role of P-glycoprotein in the intestinal absorption of tanshinone IIA, a major active constituent from the root of Salvia miltiorrhizaCurrent Drug Metabolism2007; 8(4): 325-340.
  • Yu XY, Lin SG, Zhou ZW, Chen X, Liang J, Yu XQ, Chowbay B, Wen JY, Duan W, Chan E, Li XT, Cao J & Zhou SF*.Role of P-glycoprotein in limiting the brain penetration of glabridin, an active isoflavan from the root of Glycyrrhiza glabra. Pharmaceutical Research 2007; 24(9):1668-1690.
  • Zhou SF*& Chowbay B. Clinical significance of thiopurine S-methyltransferase gene polymorphisms. Current Pharmacogenomics (presently ‘Current Pharmacogenomics & Personalized Medicine’)2007: 5(2): 103-115.
  • Zhou SF*, Xue CCL, Yu XQ, Li CG& Wang GJ. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Therapeutic Drug Monitoring 2007; 29(6): 687-710.
  • Zhou SF*, Xue CCL, Yu XQ& Wang GJ. Metabolic activation of herbal and dietary components and its clinical and toxicological implications. Current Drug Metabolism 2007; 8(6): 526-553.
  • Zhou SF*, Zhou ZW, Chen X, Li CG, Xue CCL & Herington A.Identification of drugs that interact with herbal medicines. Drug Discovery Today 2007; 12(15-16): 664-673.
  • Zhou SF*. Chinese herbal medicines for toxicity reduction in cancer chemotherapy.  Australian Journal of AcupunctureandChinese Medicine 2007; 2(2):35-37.
  • Zhou SF*. ERCC1 and non-small-cell lung cancer.New England Journal of Medicine2007; 356(24): 2540.
  • Zhou SF*. HLA polymorphisms and genetic markers and Traditional Chinese Medicine. The Journal of Alternative & Complementary Medicine 2007; 13(4):641.
  • Zhou SF*. Reply to Dr Birdsall’s Letter to the Editor. Toxicology andApplied Pharmacology 2007; 220(1): 109-110.
  • Zhou ZL, Yang M, Peng HY, Shan ZX, Chen SZ, Lin QX, Liu XY, Chen TF, Lin SG, Zhou SF*& Yu XY. A rapid and simple high-performance liquid chromatography method for the determination of human plasma levofloxacin concentration and its application to a bioequivalence study. Biomedical Chromatography 2007; 21(10): 1045-1051.
  • Zhou ZW, Chen X, Liang J, Yu XY, Wen JY& Zhou SF*. Involvement of P-glycoprotein and multidrug resistance associated protein 1 in the transport of tanshinone IIB, a primary active diterpenoid quinone from the root of Salvia miltiorrhiza, across the blood-brain barrier. Drug Metabolism Letters 2007; 1(3): 205-217.
  • Bi HC, Zhao LZ, Zhong GP, Zhou SF, Li B, Deng Y, Chen X & Huang M. High-throughput determination of carbocysteine in human plasma by liquid chromatography-tandem mass spectrometry: application to a bioequivalence study of two formulations in healthy volunteers. Rapid Communications in Mass Spectrometry 2006; 20(7): 1153-1160.
  • Bian JS, Yong QC, Pan TT, Feng ZN, Ali MY, Zhou SF& Moore PK. Role of hydrogen sulphide in the cardioprotection caused by ischemic preconditioning in the rat heart and cardiac myocytes. Journal of Pharmacology and Experimental Therapeutics2006; 316(2):670-678.
  • Boelsterli UA, Ho HK, Zhou SF& Leow KY. Bioactivation and hepatotoxicity of nitroaromatic drugs. Current Drug Metabolism 2006; 7(7): 715-727.
  • Chan E, Zhou SF, Srikumar S& W Duan. Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model. Pharmaceutical Research 2006; 23(4): 729-741.
  • Chen J, Huang M, He M, Duan W, Eli Chan, Chen X & Zhou SF*. Small interfering RNA-mediated silencing of cytochrome P450 3A4 gene. Drug Metabolism and Disposition 2006; 34(9):1650-1657.
  • Chen X, Hu ZP, Huang M, Gao YH, Yang XX, Tang WB, Chan SY, DaiXH, Ye JX, Ho PC, Duan W, Yang HY, Zhu YZ & Zhou SF*.Monitoring of immune responses to a herbal immuno-modulator in patients with advanced colorectal cancer. International Immunopharmacology 2006; 6(3): 499-508.
  • Guan S, Huang M, Ee PL, Chan E, Chen X, Duan W& Zhou SF*. Genetic polymorphisms of cytochrome P450 2B6 gene in Han Chinese. European Journal of Pharmaceutical Sciences 2006; 29(1): 14-21.
  • Guan S, Huang M, Li X, Chen X, Chan E & Zhou SF*. Intra- and inter-ethnic differences in the allele frequencies of cytochrome P450 2B6 gene in Chinese. Pharmaceutical Research2006; 23(9):1983-1990.
  • Gui JG, Song Y, Hana NL, Zhou SF& Sheu FS. Involvement of the GC-rich sequence and specific proteins (Sp1/Sp3) in the basal transcription activity of neurogranin gene. Biophysical and Biochemical Rapid Communications 2006; 345(1):124-132.
  • Hu R, Zhou SF& Li XT. Altered Bcl-2 and Bax expression is associated with cultured first trimester human cytotrophoblasts apoptosis induced by hypoxia. Life Sciences 2006; 79(4): 351-355.
  • Hu ZP, Chen X, Yang XX, Gao YH & Zhou SF*. Water-soluble polysaccharides of Ganoderma lucidum (W.Curt.:Fr.) P. Karst. (Aphyllophoromycetideae) alleviate the dose-limiting toxicities of irinotecan (CPT-11). International Journal of Medicinal Mushrooms2006; 8(4): 321-328.
  • Hu ZP, Yang XX, Chan SY, Xu AL, Duan W, Zhu YZ, Sheu FS, Boelsterli UA, Chan E, Zhang Q, Wang JC, Ee PL, Koh HL, Huang M & Zhou SF*. St. John’s wort attenuates irinotecan-induced diarrhea via down-regulation of intestinal pro-inflammatory cytokines and inhibition of intestinal epithelial apoptosis. Toxicology and Applied Pharmacology 2006; 216(2):225-237.
  • Koh HL, Wang HS, Zhou SF, Chan E & Woo SO. Detection of aristolochic acid I, tetrandrine and fangchinoline in medicinal plants by HPLC and LC/MS. Journal of Pharmaceutical and Biomedical Analysis2006; 40(3):653-661.
  • Lim WG, Tan BJ, Zhu YM, Zhou SF, Armstrong JS, Li QT, Dong QH, Chan E, Smith D, Verma C, Tan SL & Duan W.The very C-terminus of PRK1/PKN is essential for its activation by RhoA and downstream signaling. Cellular Signalling 2006; 18(9): 1473-1481.
  • Loh KP, Low LS, Wong WH, Zhou SF, Chou WH & Zhu YZ.A comparison study of cerebral protection using Ginkgo biloba extract and losartan on stroked rats. Neuroscience Letters 2006; 398(1-2):28-33.
  • Tian Q, Zhang J, Chan SY, Tan TM, Duan W, Huang M, Zhu YZ, Chan E, Yu Q, Nie YQ, Ho PC, Li Q, Ng LK, Yang HY, Hong W, Bian JS & Zhou SF*. Topotecan is a substrate for multidrug resistance associated protein 4. Current Drug Metabolism 2006; 7(1): 105-118.
  • Yang XX, Hu ZP& Zhou SF*. Acyl drug glucuronides: reactivity and analytical implications. Current Pharmaceutical Analysis 2006; 2(3): 259-277.
  • Yang XX, Hu ZP& Zhou SF*. Monitoring drug-protein interaction. Clinica Chimica Acta 2006; 365(1/2): 9-29.
  • Yang XX, Hu ZP, Chan SY & Zhou SF*. Pharmacokinetics of recombinant human endostatin in rats. Current Drug Metabolism2006; 7(6):565-576.
  • Yang XX, Hu ZP, Chan SY, Duan W, Chan E, Boelsterli UA, Ng KY, Chan YZ, Bian JS & Zhou SF*. Pharmacokinetic mechanisms for reduced toxicity of irinotecan by coadministered thalidomide. Current Drug Metabolism2006; 7(4): 431-455.
  • Yang XX, Hu ZP, Duan W, Yang H, Zhu YZ& Zhou SF*. Drug-herb interactions: eliminating toxicity with hard drug design. Current Pharmaceutical Design 2006; 12(35): 4649-4664.
  • Yang XX, Hu ZP, Xu AL, Duan W, Zhu YZ, Huang M, Sheu FS, Zhang Q, Boelsterli UA, Bian JS, Chan E, Li X, Wang JC & Zhou SF*. A mechanistic study on reduced toxicity of irinotecan by coadministered thalidomide, a tumor necrosis factor-a inhibitor. Journal of Pharmacology and Experimental Therapeutics 2006; 319(1):82-104.
  • Yeong SS, Zhu Y, Smith D, Verma C, Lim WG, Tan BJ, Li QT, Cheung NS, Cai M, Zhu YZ, Zhou SF, Tan SL&Duan W. The last 10 amino acid residues beyond the hydrophobic motif are critical for the catalytic competence and function of protein kinase Cα. Journal of Biological Chemistry 2006; 281(41):30768-30781.
  • Zhang J, Huang M, Guan S, Bi HC, Pan Y, Duan W, Chan SY, Chen X, Hong YH, Bian JS, Yang HY & Zhou SF*.A mechanistic study of the intestinal absorption of cryptotanshinone, the major active constituent of Salvia miltiorrhiza. Journal of Pharmacology and Experimental Therapeutics 2006; 317(3):1285-1294.
  • Zhang J, Tian Q & Zhou SF*. Clinical pharmacology of cyclophosphamide and ifosfamide. Current Drug Therapy 2006; 1(1):104-168.
  • Zhang J, Tian Q, Zhu YZ, Xu AL& Zhou SF*. Reversers of resistance to oxazaphosphorines. Current Cancer Drug Targets2006; 6(5): 385-407.
  • Zhang JP, Zhou SF*, Guan YY, Xu AL, Wu JH, Wei H, Chen X & Huang M. Determination of intra-ethnic differences in the polymorphisms of thiopurine S-methyltransferase in Chinese. Clinica Chimica Acta 2006; 365(1/2): 337-341.
  • Zhao LZ, Huang M, Chen J, Chen X, Hong YH, Chan SY, Ee PL & Zhou SF*. Induction of propranolol metabolism by Gingko biloba extract EGb 761 in the rat. Current Drug Metabolism 2006; 7(6): 577-787.
  • Zhong SL, Yang XY, Liang LQ, Ee PL, Wang YX, Romkes M, Duan W, Huang M & Zhou SF*. Relationship of glutathione S-transferase genotypes with side effects of pulsed cyclophosphamide therapy in patients with systemic lupus erythematosus. British Journal of Clinical Pharmacology 2006; 62(4): 457-472.
  • Zhong SL, Zhou SF*, Chan SY, Chan E, Ng KY, Chen X, Duan W & Huang M. Relationship between genotype and enzyme activity of glutathione S-transferases M1 and P1 in Chinese. European Journal of Pharmaceutical Sciences 2006; 28(1-2):76-85.
  • Zhong SL, Zhou SF*, Chen Xiao & Huang M. Rapid determination of common mutations in glutathione S-transferase gene by PCR-based methods in healthy Chinese. Clinica Chimica Acta 2006; 364(1-2): 205-208.
  • Zhou SF*. Clinical pharmacogenomics of thiopurine S-methyltransferase. Current Clinical Pharmacology 2006; 1(1): 119-128.
  • Zhou SF*. Alternative Medicine — evidence-based herbal medicine: My experience with Lingzhi (Ganoderma lucidum). Asia Pacific Biotechnology News 2006; 10(4): 209-212.
  • Zhou SF*. Cover story: Herbal medicine & drug interactions. Innovations 2006; 6(3): 1-3.
  • Zhou SF*. My teaching philosophy. CDTLink (Published by the Centre for Development of Teaching and Learning, National University of Singapore, Singapore) 2006; 10(1):5-6.
  • Zhou SG, Zhou SF, Huang HQ, Chen JW, Huang M & Liu PQ.Proteomic analysis of hypertrophied myocardial protein patterns in renovascularly hypertensive and spontaneously hypertensive rats. Journal of Proteome Research2006; 5(11): 2901-2908.
  • Zhu YM, Smith D, Verma C, Lim WG, Tan BJ, Armstrong JS, Zhou SF, Chan E, Tan SL, Zhu YZ, Cheung NS& Duan W. The very C-terminus of protein kinase Ce is critical for the full catalytic competence but its hydrophobic motif is dispensable for the interaction with 3-phosphoinositide-dependent kinase-1. CellularSignalling2006; 18(6): 807-818.
  • Balram C, Zhou SF*& Lee ETJ. An interethnic comparison of polymorphisms of the genes encoding drug metabolizing enzymes and drug transporters: Experience in Singapore. Drug Metabolism Reviews 2005; 37(2):323-374.
  • Bi HC, Zhong GP, Huang M, Zhou SF, Huang LH, Zeng GX, Liao XX, Chen X & Pang Y. Bioequivalence evaluation of two tablet formulations of carbocysteine in healthy Chinese men. The Journal of Applied Research 2005; 5(4): 598-604.
  • Bi HC, Zhong GP, Zhou SF*, Chen X & Huang M. Determination of adefovir in human plasma by liquid chromatography-tandem mass spectrometry method: application to a pharmacokinetic study. Rapid Communications in Mass Spectrometry 2005; 19(20): 2911-2917.
  • Chen Q, Chao R, Chen H, Hou X, Yan H, Zhou SF, Peng W& Xu AL. Antitumor and neurotoxic effects of novel harmine derivatives and structure-activity relationship analysis. International Journal of Cancer 2005; 114(5): 675-682.
  • Gao YH, Gao H, Chan E, Tang WB, Li XT, Liang J & Zhou SF*. Protective effects of Ganoderma (a mushroom with medicinal properties) against various liver injuries. Food ReviewsInternational2005; 21(1): 27-52.
  • Gao YH, Gao H, Chan E, Tang WB, Xu AL, Yang HY, Huang M, Lan J, Li XT, Duan W, Xu CJ & Zhou SF*. Antitumour activity and underlying mechanisms of Ganopoly, the refined polysaccharides extracted from Ganoderma lucidum, in mice. Immunological Investigations2005; 34(1): 1-28.
  • Gao YH, Tang WB, Dai XH, Gao H, Chen GL, Ye JX, Chan E, Huang M &ZhouSF*. Immune responses to water-soluble Ganoderma lucidum polysaccharides in patients with advanced colorectal cancer. International Journal of Medicinal Mushrooms 2005; 7(4): 525-538.
  • Gao YH, Tang WB, Dai XH, Gao H, Chen GL, Ye JX, Chan E, Koh HL, Li XT & Zhou SF*. Effects of water-soluble Ganoderma lucidum polysaccharides on the immune functions of patients with advanced lung cancer. Journal of Medicinal Food 2005; 8(2):159-168.
  • Gao YH, Tang WB, Gao H, Chan E, Lan J, Li XT& Zhou SF*. Antimicrobial activity of the medicinal mushroom Ganoderma.Food Reviews International 2005; 21(2):1-19.
  • Hu ZP, Yang XX, Ho PC, Chan E, Chan SY, Xu CJ, Li XT, Zhu YZ, Duan W, Chen X, Huang M, Yang HY & Zhou SF*. St. John’s wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats. Pharmaceutical Research2005; 22(6): 902-914.
  • Hu ZP, Yang XX, Ho PCL, Chan SY, Heng PWS, Chan E, Duan W, Koh HL & Zhou SF*. Herb-drug interactions: A literature review. Drugs 2005; 65(9):1-44.
  • Li J, Zhou SF, Hung H & Chan E. Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline. Pharmaceutical Research 2005; 22(3): 397-404.
  • Li J, Zhou SF, Hung H, Duan W& Chan E. Alteration of the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, due to acute gastrointestinal toxicity of doxorubicin. Pharmaceutical Research 2005; 22(11): 1954-1963.
  • Li X, Zheng D, Zhou SF, Tang D, Wang C & Wu G. Approximate entropy of fetal heart rate variability as a predictor of fetal distress in women at term pregnancy. Acta Obstetricia et Gynecologica Scandinavica2005; 84(90): 837-843.
  • Paxton JW, Kestell P, Chiang D, Zhou SF& Lewis DFV.Inhibition of human CYP1A2 oxidation of 5,6-dimethyl-xanthenone-4-acetic acid by acridines:a molecular modelling study. Clinical and Experimental Pharmacology and Physiology2005; 32(8):633-639.
  • Tang WB, Gao YH, Chen GL, Gao H, Dai XH, Ye JX, Chan E, Huang M & Zhou SF*. A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract (Ganopoly) in neurasthenia (chronic fatigue syndrome). Journal of Medicinal Food 2005; 8(1): 53-58.
  • Tian Q, Zhang J, Chan E, Duan W & Zhou SF*. Multidrug resistance proteins (MRPs) and implication in drug development. Drug Development Research 2005; 51(2):1-18.
  • Tian Q, Zhang J, Tan TM, Chan E, Duan W, Chan SY, Boelsterli UA, Ho PC, Yang H, Bian JS, Huang M, Zhu YZ, Xiong WP, Li XT & Zhou SF*. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharmaceutical Research 2005; 22(11): 1837-1853.
  • Wei H, Zhou SF*, Li CR, Zhang JP, Wu JH, Chen X & Huang M. Phenotyping and genotyping studies of thiopurine S-methyltransferase in Kazaks. Pharmaceutical Research 2005; 22 (10): 1762-1766.
  • Yang XX, Hu ZP, Chan SY, Goh BC, Chan E, Duan W & Zhou SF*. Novel agents that potentially inhibit CPT-11-induced diarrhea. Current Medicinal Chemistry2005; 12(10): 763-781.
  • Yang XX, Hu ZP, Chan SY, Goh BC, Chan E, Ho PC & Zhou SF*. Simultaneous determination of the lactone and carboxylate forms of irinotecan (CPT-11) and its active metabolite SN-38 by high performance liquid chromatography: application to plasma pharmacokinetic studies in the rat. Journal of Chromatography B: Analytical Technologies in Biomedical and Life Sciences 2005; 821(2): 221-228.
  • Yang XX, Hu ZP, Chan SY, Goh BC, Ho PC, Chan E, Duan W& Zhou SF*. Determination of thalidomide by high performance liquid chromatography: plasma pharmacokinetic studies in the rat.  Journal of Pharmaceutical and Biomedical Analysis2005; 39(1-2): 299-304.
  • Zhang J, Tian Q, Chan SY, Duan W& Zhou SF*. Insights into the resistance to oxazaphosphorines and potential approaches to its circumvention. Drug Resistance Updates 2005; 8(5): 271-297.
  • Zhang J, Tian Q, Chan SY, Duan W, Li SC, Zhu YZ & Zhou SF*. Metabolism and transport of oxazaphosphorines and the clinical implications. Drug Metabolism Reviews 2005; 37 (4):1-93.
  • Zhong GP, Bi HC, Zhou SF, Chen X & Huang M. Simultaneous determination of metformin and gliclazide in human plasma by liquid chromatography-tandem mass spectrometry method: application to a bioequivalence study of two formulations in healthy Chinese volunteers. Journal of Mass Spectrometry 2005; 40(11):1462-1471.
  • Zhong SL, Zhou SF*& Huang M. A comparison of glutathione S-transferase mutant frequencies in healthy Han and Uygur Chinese. European Journal of Drug Metabolism and Pharmacokinetics2005;30(3):181-185.
  • Zhong SL, Wang YX, Zhou SF& Huang M. Impact of GSTM1 and GSTP1 gene polymorphisms on erythrocyte GST activity. Chinese Pharmacological Bulletin 2005; 21(6): 726-726.
  • Zhou Q, Zhou SF& Chan E. Effect of coenzyme Q10 on warfarin hydroxylation in rat and human liver microsomes. Current Drug Metabolism 2005; 6(2): 67-81.
  • Zhou Q, Zhou SF& Chan E. Effect of omeprazole on the hydroxylation of warfarin enantiomers in human: in-vitro studies with liver microsomes and cDNA-expressed cytochrome P450 isozymes. Current Drug Metabolism 2005; 6(5): 399-411.
  • Zhou SF*, Chan E, Duan W, Huang M & Chan YZ. Drug bioactivation, covalent binding to target proteins and toxicity relevance. Drug Metabolism Reviews 2005: 37(1): 41-213.
  • Zhou SF*, Chan E, Li XT & Huang M. Clinical outcomes and management of mechanism-based inhibition of cytochrome P450 3A4. Therapeutics and Clinical Risk Management2005; 1(1): 3-13.
  • Zhou SF*,Chan SY, Goh BC, Chan E, Duan W, Huang M & McLeod HL. Mechanism-based inhibition of CYP3A4 by therapeutic drugs. Clinical Pharmacokinetics 2005; 44(4):1-27.
  • Zhou SF*, Feng X, Kestell P, Baguley BC, Paxton JW &Chan E. Transport of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide by human intestinal Caco-2 cells. EuropeanJournal of Pharmaceutical Sciences 2005; 25(4): 513-524.
  • Zhou SF*, Gao YH& Eli Chan. Clinical trials for medicinal mushrooms: experience with Ganoderma lucidum (W.Curt.:Fr) Lloyd (Lingzhi mushroom). International Journal of Medicinal Mushrooms 2005; 7(2): 105-111.
  • Zhou SF*, Huang M, Xu AL, Yang H, Duan W & Paxton JW. Prediction of metabolic herb-drug interactions: a simulation study. Phytotherapy Research 2005; 19(6): 464-471.
  • Zhou SF*, Li Y, Kestell P, Baguley BC, Chan E, Schafer P & Paxton JW. Transport of thalidomide by human intestinal Caco-2 cells. European Journal of Drug Metabolism and Pharmacokinetics 2005; 30(1-2):49-61.
  • Zhou SF*. Teaching of clinical pharmacogenetics for pharmacy students at the National University of Singapore. Pharmacy Education 2005; 5(3/4):235-240.
  • Zhou SF*. Potential for improving irinotecan-based cancer chemotherapy. Research Newsletter (published by Faculty of Science, National University of Singapore) 2005; 9(2): 10-12.
  • Zhou SF*. Teaching of Pharmacogenetics at NUS. CDTLink (Published by the Centre for Development of Teaching and Learning, National University of Singapore, Singapore) 2005; 9(2): 5-6.
  • Gao YH, Chan E& Zhou SF*. Immuno-modulating activities of Ganoderma,a mushroom with medicinal properties. Food Reviews International 2004; 20(2): 123-161.
  • Gao YH, Chen GL, Dai XH, Ye JX & Zhou SF*. A Phase I/II study of Lingzhi mushroom Ganoderma lucidum (W.Curt.: Fr.) LIoyd (Aphyllophoromycetideae) extract in patients with coronary heart disease. International Journal of Medicinal Mushrooms 2004; 6(4): 327-334.
  • Gao YH, Gao H, Chan E, Tan WB, Lan J, Koh HL, Chen GL & Zhou SF*. Hypoglycemic properties of polysaccharides extracted from Ganoderma lucidum in alloxan-induced diabetic rats. Journal of Food Science & Nutrition 2004; 9(3): 240-244.
  • Gao YH, Lan J, Dai XH, Ye JX & Zhou SF*. A Phase I/II trial of Ling Zhi mushroom Ganodermalucidum (W.Curt.:Fr.)Lloyd (Aphyllophoromycetideae) extract in patients with type II diabetes mellitus. International Journal of Medicinal Mushrooms 2004; 6(1): 33-39.
  • Gao YH, Tang WB, Gao H, Chan E, Lan J& Zhou SF*. Ganoderma lucidum polysaccharide fractions accelerate healing of acetic acid-induced ulcers in rats. Journal of Medicinal Food2004; 7(4): 417-421.
  • Gao YH, Tang WB, Gao H, Lan J& Zhou SF*. Chemopreventive and tumoricidal properties of Ling Zhi mushroom Ganoderma lucidum (W. Curt.:Fr.) Lioyd (Aphyllophoromycetideae). Part I. Preclinical and clinical studies. International Journal of Medicinal Mushrooms 2004; 6(2): 95-106.
  • Gao YH, Tang WB, Gao H, Lan J& Zhou SF*. Chemopreventive and tumoricidal properties of Ling Zhi mushroom Ganoderma lucidum (W. Curt.:Fr.) Lioyd (Aphyllophoromycetideae). Part II. Mechanism considerations. Internal Journal of Medicinal Mushrooms2004; 6(3): 219-230.
  • Lai T, Gao YH& Zhou SF*.Global marketing of medicinal Ling Zhi mushroom Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) products and safety concerns. International Journal of Medicinal Mushrooms 2004; 6(2): 185-190.
  • Li XT, Tang DK, Zhou SF, Zhou GX, Wang CY, Zhuang YL, Wu GQ & Shen LL. Redistribution of power spectrum of heart rate variability during acute umbilical artery embolism and hypoxemia in late-gestation fetal sheep. European Journal of Obstetrics & Gynecology and Reproductive Biology2004; 114(2): 137-143.
  • Zhang JP, Guan YY, Wu JH, Xu AL, Zhou SF& Huang M. Phenotyping and genotyping studies of thiopurine S-methyltransferase: a comparison of Han and Yao ethnic groups. British Journal of Clinical Pharmacology 2004; 58(2):163-168.
  • Zhang JP, Guan YY, Xu AL, Zhou SF, Wu JH, Wei H & Huang M. Gene mutation of thiopurine S-methyltransferase gene in Uygur Chinese. European Journal of Clinical Pharmacology 2004; 60(1):1-3.
  • Zhou SF*, Chan E, Li SC, Huang M, Li XT, Zhang Q & Paxton JW. Predicting pharmacokinetic herb-drug interactions. Drug Metabolism and Drug Interactions2004; 20(3): 145-158.
  • Zhou SF*, Chan E, Lim LY, Boelsterli UA, Li SC, Wang JC, Zhang Q, Huang M & Xu AL. Therapeutic drugs behave as mechanism-based inhibitors of cytochrome P450 3A4. Current Drug Metabolism 2004; 5(5): 415-442.
  • Zhou SF*, Chan E, Pan SQ, Huang M & Lee EJD. Pharmacokinetic interactions of drugs with St John’s wort. Journal of Psychopharmacology 2004; 18(2): 262-276.
  • Zhou SF*, Feng X, Kestell P, Baguley BC& Paxton JW. Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by high performance liquid chromatography with fluorescence detection: Application to transport studies. Journal of Chromatography B: Analytical Technologies in Biomedical & Life Sciences 2004; 801(1): 87-97.
  • Zhou SF*, Goh HL, Gao YH, Gong ZY & Lee ETJ. Herbal bioactivation: the good, the bad and the ugly. Life Sciences 2004; 74(8): 935-968.
  • Zhou SF*, Lim LY & Chowbay B. Herbal modulation of P-glycoprotein. Drug Metabolism Reviews 2004; 36(1): 57-104.
  • Gao YH, Dai XH, Chen GL, Ye JX & Zhou SF*. A randomized, placebo-controlled, multicenter study of Ganoderma lucidum (W.Curt.:Fr.) Lloyd (Aphyllophoromycetideae) polysaccharides (Ganopoly®) in patients with advanced lung cancer. International Journal of Medicinal Mushrooms 2003; 5(4): 383-395.
  • Gao YH, Zhou SF*, Jiang WQ, Huang M& Dai XH. Effect of Ganopoly, a Ganoderma lucidum polysaccharideextract on the immunological function in advanced-stage cancer patients. Immunological Investigations2003; 32(3): 201-215.
  • Zhou SF*, Kestell P, Baguley BC & Paxton JW. Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochemical Pharmacology 2003; 65(1): 109-120.
  • Zhou SF*, Kestell P, Baguley BC& Paxton JW. Preclinical factors affecting the interindividual variability in the clearance of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochemical Pharmacology 2003; 65(11): 1853-1865.
  • Gao YH & Zhou SF*. Cancer prevention and treatment by Ganoderma, a mushroom with medicinal properties. Food Reviews International 2003; 19(3): 275-325.
  • Gao YH, Lin ZB, Huang M & Zhou SF*. Hepatoprotective activity and the mechanisms of action of Ganoderma lucidum (Curt.: Fr) P. Karst (Ling Zhi, Reishi Mushroom) (Aphyllophoromycetideae). Internal Journal of Medicinal Mushrooms 2003;5(2): 113-133.
  • Gao YH, Zhou SF*, Huang M & Xu AL.Antibacterial and antiviral value of the genus Ganoderma P. Karst. Species (Aphyllophoromycetideae): a review. International Journal of Medicinal Mushrooms 2003; 5(3): 235-246.
  • Zhou SF*, Gao YH, Huang M, Xu AL & Paxton JW. Interactions of herbs with cytochrome P450. Drug Metabolism Reviews 2003; 35(1): 35-98.
  • Zhou SF*. Separation and detection methods for covalent drug-protein adducts. Journal of Chromatography B: Analytical Technologies in Biomedical and Life Sciences2003; 797(1-2): 63-90.
  • Zhou SF*. Correspondence re: J. Lu et al., Thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9: 1680-1688, 2003. Clinical Cancer Research 2003; 9(14): 5429.
  • Zhou SF*. CYP1A1-mediated activation of thalidomide and suppression of embryo fibroblast proliferation. Drug Metabolism and Disposition 2003; 31(8): 1072.
  • Zhou SF*, Li Y, Kestell P & Paxton JW. Determination of thalidomide in transport buffer for Caco-2 monolayers by high performance liquid chromatography. Journal of Chromatography B:Analytical Technologies in Biomedical and Life Sciences 2003; 785(1): 165-173.
  • Gao YH, Zhou SF*, Chen GL, Dai XH & Ye JX. A Phase I/II study of a Ganoderma lucidum (Curt.: Fr.) P. Karst. extract (Ganopofy) in patients with advanced cancer. International Journal of Medicinal Mushrooms 2002; 4(3): 207-214.
  • Gao YH, Zhou SF*, Chen GL, Dai XH, Ye JX & Gao H.A Phase I/II study of a Ganoderma lucidum (Curt.: Fr.) P. Karst. (Ling Zhi, Reishi Mushroom) extract in patients with chronic hepatitis B. International Journal in Medicinal Mushrooms 2002; 4(4): 321-327.
  • Gao YH, Zhou SF*, Wen JB, Huang M & Xu AL. Mechanisms for the antiulcerogenic effects of Ganoderma lucidum polysaccharide fraction on indomethacin-induced ulcer in the rat. Life Sciences2002; 72(6): 731-745.
  • Zhou SF*&Gao YH. The immuno-modulating effects of Ganoderma lucidum (Curt.:ZFr.) P. Karst. (Ling Zhi, Reishi Mushroom) (Aphyllophoromycetideae).International Journal of Medicinal Mushrooms 2002; 4(1): 1-11.
  • Zhou SF*, Chin R, Kestell P & Paxton JW. High throughput screening for the potential inhibitors for the metabolism of the novel anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid in human liver microsomes. Journal of Chromatography B: Analytical Technologies in Biomedical and Life Sciences 2002; 767(1): 19-26.
  • Zhou SF, Kestell P & Paxton JW. 6-Methylhydroxylation of the anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by flavin-containing monooxygenase 3. European Journal of Drug Metabolism and Pharmacokinetics 2002; 27(3): 179-183.
  • Zhou SF, Kestell P & Paxton JW. Non-specific binding of the experimental anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid by microsomes from various species.Journal of Pharmacy and Pharmacology2002; 54(7): 997-1004.
  • Zhou SF*, Kestell P, Baguley BC & Paxton JW. 5,6-Dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy. Investigational New Drugs 2002; 20(3): 281-295.
  • Zhou SF, Paxton JW & Kestell P.Strain differences in the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid in mice. Journal of Chromatography B: Analytical Technologies in Biomedical & Life Sciences 2002; 776(2): 231-236.
  • Zhou SF, Paxton JW,Tingle MD & Kestell P. Gender differences in the metabolism and pharmacokinetics of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in the mouse, rat and human. Cancer Chemotherapy and Pharmacology2002; 49(2): 126-132.
  • Zhou SF, Paxton JW,Tingle MD & Kestell P.Predicting pharmacokinetic variability and drug interactions with preclinical approaches: the experience with the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Drug Metabolism Reviews 2002; 34(4): 751-790.
  • Zhou SF, Paxton JW, Tingle MD& Kestell P. Species differences in the metabolism of the novel antitumour agent5,6-dimethylxanthenone-4-acetic acid in mouse, rat, rabbit and human liver microsomes: implications for prediction of metabolic interactions in vivo. Xenobiotica 2002; 32(2): 87-107.
  • Zhou SF*, Paxton JW, Tingle MD & Kestell P. Thalidomide in the treatment of cancer: a potential role in the elderly. Drug Aging 2002; 19(2): 85-100.
  • Zhou SF, Chin R, Tingle MD, Kestell P & Paxton JW. Effects of anti-cancer drugs on the metabolism of the anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by human liver microsomes. British Journal of Clinical Pharmacology 2001; 52(2): 129-136.
  • Zhou SF, Paxton JW, Tingle MD & Kestell P. A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide. Cancer Chemotherapy and Pharmacology 2001; 47(6): 541-544.
  • Zhou SF, Paxton JW, Tingle MD & Kestell P. Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography.Journal of Chromatography B: Analytical Technologies in Biomedical & Life Sciences 2001;757(2): 343-348.
  • Zhou SF, Paxton JW, Tingle MD & Kestell P. Determination of unbound concentration of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection. Journal of Chromatography B: Analytical Technologies in Biomedical and Life Sciences 2001; 757(2): 359-363.
  • Zhou SF, Paxton JW, Tingle MD & Kestell P. In vitro and in vivo kinetic interactions between the novel antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac. Cancer Chemotherapy & Pharmacology 2001; 47(4): 319-326.
  • Zhou SF, Paxton JW, Tingle MD & Kestell P. Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species. Journal of Pharmacy and Pharmacology 2001; 53(4): 463-471.
  • Zhou SF, Paxton JW, Tingle MD, Kestell P, Jameson MB & Baguley BC. Identification and reactivity of the major metabolite (b-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans. Xenobiotica 2001; 31(5): 277-293.
  • Zhou SF, Paxton JW, Tingle MD & Kestell P. Identification of the cytochrome P450 isoenzyme for the 6-methylhydroxylation of the novel antitumour agent 5,6-dimethylxanthenone-4-acetic acid.Drug Metabolism and Dispositions 2000; 28(12): 1449-1456.
  • Zhou SF, Paxton JW, Tingle MD, McCall J & Kestell P. Determination of two major metabolites of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection. Journal of Chromatography B: Analytical Technologies in Biomedical & Life Sciences 1999; 734(1): 129-136.
  • Wu HS, Nie YQ, Li YY & Zhou SF. The carcinogenesis and treatment of adenomatous polyps (腺瘤性息肉的癌变及治疗). Academic Journal of Guangzhou Medical College (广州医学院学报) 1998; 26(5): 12-14.
  • Wu HS, Nie YQ, Li YY& Zhou SF. The carcinogenesis and treatment of adenomatous polyps in the digestive system (肠道腺瘤性息肉的癌变及治疗). Chinese Journal of Digestive Endoscopy (中华消化内镜杂志) 1997; 14(1):5-7.
  • Zhou SF, Li YY, Wu HS & Nie YQ. The clinical efficacy and cost of three types of triple therapies for HP-positive ulcer (三种三联疗法对 HP 阳性的消化性溃疡的疗效和治疗成本的比较). Journal ofModernDigestive Disease& Endoscopy(现代消化病及内镜杂志) 1996; 1(1): 32-34.
  • Li YY, Wu HS, Nie YQ & Zhou SF.Clinical efficacy of losec plus ampicillin for the treatment of HP-positive peptice ulcer (洛赛克加羟氨苄青霉素对治愈十二指肠溃疡和根除幽门螺杆菌疗效). Guangzhou Medical Journal (广州医药) 1995; 26(5): 5-7.
  • Nie YQ, Li YY, Wu HS & Zhou SF. Risk of distal colonic adenomas with synchronous proximal colonic adenomas (大肠远侧腺瘤者存在大肠近侧息肉的危险性). Chinese Journal of Digestive Endoscopy (中华消化内镜杂志) 1995; 12(6): 326-329.
  • Wu HS, Nie YQ, Li YY & Zhou SF. The differentiating diagnosis of jaundice by endoscopic retrograde cholangiopancreatography (ERCP) (内镜下逆行胆管造影对黄疸的鉴别诊断). Guangzhou Medical Journal (广州医药) 1995; 26(5): 9-10.
  • Zhou SF*& Li YY. Acute abdominal pain due to gastrointestinal diseases (胃肠内科疾病所致的急腹痛). New Medicine(新医学) 1995; 26(5): 230-231.
  • Zhou SF*, Li YY & Wu HS. Determination of hexosamine in gastric mucus in patients with Helicobacter pylori infection (幽门螺杆菌感染对胃粘膜氨基己糖水平的影响). Chinese Journal of Pathophysiology(中国病理生理杂志) 1995; 11(1): 33-33.
  • Zhou SF*& Li YY. Recent progress in the study of primary hemochromatosis (原发性血色病的研究进展). Guangzhou Medical Journal (广州医药) 1995; 26(5): 3-4.
  • Zhou SF*, Wu HS& Li YY. The diagnosis and management of acute hemorrhagic enteritis (急性出血坏死性肠炎诊治). Guangzhou Medical Journal(广州医药) 1995; 26(1): 53-54.
  • Zhou SF*& Ou BX. The study of mutagenicity of sodium selenite in human & mammalian cell, bacterium and its estimate of carcinogenicity (亚硒酸钠对人和哺乳动物细胞, 细菌的诱变作用研究及其致癌性的初步评估). Studies ofTrace Element&Health(微量元素与健康研究) 1994; 11(2): 4-6.
  • Zhou SF*& Li YY.Effect of Helicobacter pylori infection on gastric hexosamine levels (幽门螺杆菌感染对胃粘膜氨基已糖水平的影响). Guangdong Medical Journal (广东医学) 1994; 15(6): 410-411.
  • Zhou SF*, Li YY, Wu HS& Nie YQ. Clinical diagnosis and management of gastrointestinal bleeding due to portal hypertension (肝硬化门脉高压并上消化道出血的判别分析). Chinese Journal ofClinical Gastroenterology (临床消化病杂志) 1994; 10(1): 55-56.
  • Zhou SF*, Wu HS, Li YY & Nie YQ. The clinical features of hemochromatosis in Chinese patients - a case report and literature review of 17 cases (国人原发性血色病的临床特点—1 例报告及 17 例综述). Journal ofClinical Gastroenterology(临床胃肠病学杂志) 1994; 6(3): 129-130.
  • Li YY, Hu PJ, Wu HS, Cui Y & Zhou SF*. Efficacy and toxicity of Shiweishu on chronic gastritis (施维舒对慢性胃炎及胃溃疡的临床疗效). New Medicine(新医学) 1994; 25(3): 125-128.
  • Pan JG, Li YY, Wu HS & Zhou SF. The therapeutic effect of San个wanmi on chronic gastritis and skin disorders (桑王蜜对慢性胃炎和皮肤异常的辅助治疗作用). Journal of Bee (蜜蜂杂志) 1994; 9: 3-4.
  • Wu HS, Nie YQ, Li YY & Zhou SF. The endoscopic findings and Helicobacter pylori infection status in 384 patients after partial gastrectomy (384 例胃部分切除术后胃镜检查结果分析及幽门螺杆菌调查). Guangzhou Medical Journal (广州医药) 1993; 24(6): 9-9.
  • Zhou SF*, Li YY & Wu HS. Endoscopic manifestations of peptic ulcers due to portal hypertension (肝硬化门脉高压合并消化性溃疡的内镜表现). Journal of Guangzhou Medicine(广州医药) 1993; 24(6): 10-11.


 

Shufeng Zhou

Professor

 

  • : 813 9746276
    Fax:813 9059885

  • DEPARTMENT

    College of Pharmacy & Morsani College of Medicine
    University of South Florida (USF)

     

  • COUNTRY USA